Evidence map›Paper›PMID 41194018›Full record

ArticleBMC microbiology2025

In vitro combination effects and mechanisms of Revaprazan with Triazole antifungal drugs on Aspergillus.

Wenxu Cheng, Min Shen, Lijia Wan, Tian Chen, Lingxi Wang, Heng Zhang, Yi Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenxu Cheng *Department of Otolaryngology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, 434020, China.
Min Shen *Department of Otolaryngology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, 434020, China.
Lijia WanDepartment of Otolaryngology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, Hubei, 434020, China.
Tian ChenHubei Provincial Clinical Research Center for Diagnosis and Therapeutics of Pathogenic Fungal Infections, Jingzhou, Hubei, China.
Lingxi WangHubei Provincial Clinical Research Center for Diagnosis and Therapeutics of Pathogenic Fungal Infections, Jingzhou, Hubei, China.
Heng ZhangHubei Provincial Clinical Research Center for Diagnosis and Therapeutics of Pathogenic Fungal Infections, Jingzhou, Hubei, China.
Yi SunHubei Provincial Clinical Research Center for Diagnosis and Therapeutics of Pathogenic Fungal Infections, Jingzhou, Hubei, China. jzzxyysy@163.com.

Funding

Jingzhou Science and Technology Plan Project grant numbers 2024HD34the Key Research and Development program of Hubei Province 2024BCB043Yangtze University Science and Technology Aid to Tibet Medical Talent Training Program Project grant numbers 2023YZ06
6 · The paper itself

Abstract

Potassium-competitive acid blockers (P-CABs), such as revaprazan (REV), act by competitively inhibiting potassium (K

Indexed as

Antifungal AgentsAspergillusTriazolesAspergillosisDrug SynergismFungal ProteinsHumansMicrobial Sensitivity TestsVoriconazoleAntifungal AgentsFungal ProteinsTriazolesVoriconazoleAcid pump antagonistAzolesMFS transporterRevaprazan hydrochloride

Identifiers

PMID41194018
PMCPMC12587714

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.